Trials / Recruiting
RecruitingNCT04913805
Matching Perfusion and Metabolic Activity in HFpEF
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (estimated)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test whether pharmacologic agents that increase perfusion \[Potassium Nitrate (KNO3)\], with and without additional supplements that may improve mitochondrial function \[Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Detailed description
This study will test whether Potassium Nitrate (KNO3), with and without Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR), improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF). Additionally, the study will test whether the response to supplemental oxygen during a standardized MRI assessment of skeletal muscle oxidative capacity can identify HFpEF individuals who preferentially will benefit from either KNO3 alone or the combination of pharmacologic agents (KNO3 + PLC + NR)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Potassium Nitrate | Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle |
| DRUG | Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside | Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR) |
| OTHER | Potassium Chloride | Active control |
Timeline
- Start date
- 2021-10-11
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2021-06-04
- Last updated
- 2025-05-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04913805. Inclusion in this directory is not an endorsement.